Alcohol consumption disrupts protein that controls liver fat: Study
Exposure to excessive alcohol disrupts the activity of a protein that plays a key role in keeping liver fat healthy, a study found. Researchers said…
News
New Alagille syndrome therapy named ART4 gets FDA designations
The U.S. Food and Drug Administration (FDA) has granted orphan drug and rare pediatric disease designations to ART4, an experimental therapy for Alagille syndrome…
Gene-editing approach may one day cure chronic hepatitis B: Study
A gene-editing therapy designed to specifically inactivate a hidden genetic blueprint of the hepatitis B virus (HBV) — the cause of hepatitis B —…
New trial data show saroglitazar works to ease liver damage in PBC
One year of treatment with saroglitazar, Zydus Therapeutics’ experimental oral candidate, outperformed a placebo at normalizing markers of liver injury in people with…
New medications show promise for children with rare liver disease
While different types of progressive familial intrahepatic cholestasis (PFIC) vary in their genetic cause and clinical profile, new medications like Bylvay (odevixibat) and Livmarli…
Age at Kasai, spleen issues key to biliary atresia outcomes
Babies who had standard Kasai surgery when they were more than 60 days old or had spleen malformations were more likely to have poor outcomes…
Canada clears fast fingerstick test for hepatitis C
A one-hour point-of-care test for hepatitis C has been cleared for use in Canada, which could help accelerate diagnosis and monitor how people with…
Blood marker can predict liver function improvement in PBC
A blood marker of inflammation called lymphocyte-to-monocyte ratio (LMR) is an independent predictor of liver recompensation — when liver function improves with treatment despite permanent…
Targeting mitochondrial problems eases cholestasis in mouse model
Problems in mitochondria, the cell’s powerhouses, may contribute to liver damage associated with cholestasis and represent a potential therapeutic target, a study showed. Deteriorating…
Drug for fatty liver disease MASH may help prevent transplants
Regulators in the European Union (EU) have granted conditional approval to Rezdiffra (resmetirom) for some people with metabolic dysfunction-associated steatohepatitis (MASH), making it the first…
Recent Posts
- Drug combo shrinks liver fat in rats and zebrafish: Study
- Know your risks – and options – this National Liver Awareness Month
- Enrollment complete in 2 Phase 2 trials testing hepatitis B treatment
- PBC worst for life quality among autoimmune liver diseases: Study
- Changes big and small can benefit those of us with MASH